At a time when insurers are expanding their presence on state exchanges and rolling out tech-savvy portals to capture new customers, single state “Blue” insurers are finding themselves hamstrung by regulations and lack of capital.
At a time when insurers are expanding their presence on state insurance exchanges and rolling out tech-savvy portals to capture new customers, single-state “Blue” insurers are finding themselves hamstrung by regulations and lack of capital.
And unless they’re able to restructure, they’ll find themselves increasingly squeezed out of a changing market, according to a new report by Deloitte.
Single-state Blues “can’t keep up with the current pace of investment,” says Bill Copeland, vice chairman of Deloitte's U.S. Life Sciences division and the study’s lead author.
While public companies have access to currency for mergers and acquisitions to strengthen market share, stand-alone Blue Cross and Blue Shield organizations have limited cash to be able to do so, says Copeland.
That lack of capital is also hampering their ability to invest in infrastructure including new technology platforms that could expand their reach. “With currency, they can buy new capabilities,” says Copeland.
The report, Escaping Rapunzel’s Tower, analyzed 2012 health insurance company data from publicly available financial statements and National Association of Insurance Commissioners’ reports. It found that the “Big Five” insurance companies spent, on average, nearly six times more on capital expenditures than single-state Blue plans.
Unlike publicly-traded companies that answer to shareholders, the non-profit Blues are controlled by state insurance regulators. And while publicly-traded companies can sell stock to raise capital, but Blues don’t have that luxury, he notes.
NEXT: Going public is not a panacea
Having the single-state Blues restructure to become publicly-traded companies won’t necessarily help, Copeland adds. “If a single state blue went public, I don’t think it would change the competitive nature all that much. It would take consolidation on a much larger scale to effect real change.”
Outdated regulations and methodologies need to change in order to free the Blues, which he compares to Rapunzel trapped in a tower. “They need to be regulated as if they’re an asset of the state. There’s going to continue to be more change, so the question is, is all of this regulation helping or hurting the asset?”
Without change, “their performance levels will begin to drop and it will start to have an adverse impact on their income statement,” says Copeland. Industry-wide change is being driven in large part by the Affordable Care Act (ACA), he notes. “The ACA introduced choice into the marketplace. What we’re seeing now is more competition in the mix, whether it’s from retail, or hospitals, or the financial sector.”
Consumers are responding to the choice and now want to shop for health insurance the way they shop for auto and life insurance products.
The ACA also eliminated an historic competitive advantage for single-state Blues when it mandated that enrollees couldn't be denied coverage for pre-existing conditions. Prior to that, “Blues were seen as the insurer of last resort,” notes Copeland.
An answer for long-term survivability lies in broad-scale collaboration among Blues, something that has worked in the past, says Copeland. “Blues have historically worked together on (certain) initiatives like the Blue Card.”
Going forward, “they need a common agenda, which is hard to do as they’re all separate. Doing so would require that they be legally tied together. “Removing obstacles to that action would help,” says Copeland.
Premiums for Employer-based Health Insurance Increased by 7% in 2024, Says KFF Report
Published: October 9th 2024 | Updated: October 9th 2024The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Listen
We conducted our annual State of the Industry survey in the early part of November 2023. The survey had 432 respondents, of whom 56% self-reported working for a payer organization (pharmacy benefit manager, insurer or self-insured employer), 34% for a provider organization and the remainder for government or an unspecified “other” category.
Read More